PMID- 32079622
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 2059-7029 (Electronic)
IS  - 2059-7029 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Feb
TI  - Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 
      RA) plus dexamethasone for prevention and treatment of chemotherapy-induced 
      nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic 
      review and meta-analysis of randomised controlled trials.
LID - 10.1136/esmoopen-2019-000621 [doi]
LID - e000621
AB  - We performed a pooled analysis to evaluate the efficacy and adverse events (AEs) 
      of olanzapine combined with dexamethasone plus 5-hydroxytryptamine type 3 
      receptor antagonist (5-HT3 RA) compared with 5-HT3 RA plus dexamethasone for the 
      prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in 
      high and moderate emetogenic chemotherapy based on randomised controlled trials 
      (RCTs). PubMed, EMBASE, Web of Science, the Cochrane Library, China Biomedical 
      Literature database (CBM), WanFang Database, China National Knowledge 
      Infrastructure (CNKI), and Chinese Science and Technology Periodical Database 
      (VIP) (from their inception to April 2019) were searched to capture relevant 
      articles. Relative risk with 95% confidence intervals for CINV and AEs were all 
      extracted or calculated. Eleven studies with 1107 cancer patients were involved 
      in this review. The pooled RR of delayed CINV (RR 0.50, 95% CI 0.38 to 0.66; 
      p<0.01) were significantly decreased in the olanzapine group. The occurrence of 
      insomnia was also statistically decreased, as was the rate of acute CINV (RR 
      0.60, 95% CI 0.48 to 0.75; p<0.01). However, only the percentages of CINV III and 
      CINV IV were significantly decreased in the acute and delayed phases. Subgroup 
      analysis demonstrated that the efficacy was not statistically significantly 
      different between 5 mg and 10 mg olanzapine. Olanzapine significantly decreased 
      the occurrence of CINV III and IV and insomnia in high and moderately emetogenic 
      chemotherapy. Compared with 10 mg per day, 5 mg oral olanzapine may be more 
      appropriate for patients with cancer.
CI  - (c) Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No 
      commercial re-use. Published by BMJ on behalf of the European Society for Medical 
      Oncology.
FAU - Zhou, Jian-Guo
AU  - Zhou JG
AUID- ORCID: 0000-0002-5021-3739
AD  - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical 
      University, Zunyi, China.
AD  - Department of Radiation Oncology, Universitatsklinikum Erlangen, Erlangen, 
      Germany.
FAU - Huang, Lang
AU  - Huang L
AD  - Department of Oncology, Guangyuan Central Hospital, Guangyuan, China.
FAU - Jin, Su-Han
AU  - Jin SH
AD  - Department of Orthodontics, Affiliated Stomatological Hospital of Zunyi Medical 
      University, Zunyi, China.
FAU - Xu, Cheng
AU  - Xu C
AD  - Department of Oncology, Guangyuan Central Hospital, Guangyuan, China.
FAU - Frey, Benjamin
AU  - Frey B
AD  - Department of Radiation Oncology, Universitatsklinikum Erlangen, Erlangen, 
      Germany.
FAU - Ma, Hu
AU  - Ma H
AD  - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical 
      University, Zunyi, China mahuab@163.com Udo.Gaipl@uk-erlangen.de.
FAU - Gaipl, Udo S
AU  - Gaipl US
AD  - Department of Radiation Oncology, Universitatsklinikum Erlangen, Erlangen, 
      Germany mahuab@163.com Udo.Gaipl@uk-erlangen.de.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - ESMO Open
JT  - ESMO open
JID - 101690685
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Serotonin 5-HT3 Receptor Antagonists)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Antiemetics/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Dexamethasone/pharmacology/*therapeutic use
MH  - Humans
MH  - Nausea/*chemically induced
MH  - Olanzapine/pharmacology/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Serotonin 5-HT3 Receptor Antagonists/pharmacology/*therapeutic use
MH  - Vomiting/*chemically induced
PMC - PMC7046384
OTO - NOTNLM
OT  - 5-HT3 RA
OT  - chemotherapy-induced nausea and Vomiting
OT  - dexamethasone
OT  - meta-analysis
OT  - olanzapine
COIS- Competing interests: None declared.
EDAT- 2020/02/23 06:00
MHDA- 2021/07/02 06:00
PMCR- 2020/02/19
CRDT- 2020/02/22 06:00
PHST- 2019/10/19 00:00 [received]
PHST- 2019/12/03 00:00 [revised]
PHST- 2019/12/29 00:00 [accepted]
PHST- 2020/02/22 06:00 [entrez]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2020/02/19 00:00 [pmc-release]
AID - S2059-7029(20)30018-1 [pii]
AID - esmoopen-2019-000621 [pii]
AID - 10.1136/esmoopen-2019-000621 [doi]
PST - ppublish
SO  - ESMO Open. 2020 Feb;5(1):e000621. doi: 10.1136/esmoopen-2019-000621.